Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,523 across all filing types
Latest filing 2019-03-20 Capital/Financing Update
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
UPDATES ON THE SPIN-OFF AND SEPARATE LISTING OF CSPC XNW GROUP ON THE CHINEXT OF SHENZHEN STOCK EXCHANGE
Capital/Financing Update Classification · 95% confidence The document is an announcement from CSPC Pharmaceutical Group Limited regarding the spin-off and separate listing of CSPC XNW Group on the ChiNext of the Shenzhen Stock Exchange. It details the offer size, offer price per share, net proceeds, offering costs, commencement of dealings, and top shareholders after the offering. The content focuses on the fundraising event and capital structure changes related to the new share issuance and listing. There are no financial statements or comprehensive financial performance data presented, but rather an update on the capital raising and listing process. This fits the definition of a Capital/Financing Update (CAP). The document length is 7047 characters, which is sufficient to provide substantive details about the offering, not just a brief notice or report publication announcement. Therefore, the appropriate classification is CAP with high confidence.
2019-03-20 English
ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2018
Annual Report Classification · 100% confidence The document is an announcement of the annual results for the year ended 31 December 2018 by CSPC Pharmaceutical Group Limited. It contains detailed financial highlights, chairman's statement, business outlook, and consolidated financial statements including profit or loss, comprehensive income, and financial position. The content is comprehensive and includes actual financial data and analysis for the full fiscal year, which is characteristic of an Annual Report. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or a notice of report publication. The presence of audited consolidated results and detailed financial statements confirms it is the official yearly report covering company activity and full financial performance. FY 2018
2019-03-18 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from CSPC Pharmaceutical Group Limited stating the date of a board meeting to approve final results for the year ended 31 December 2018 and to consider a final dividend. It does not contain any financial data or detailed report content but merely announces the upcoming board meeting and the agenda. The length is only 1472 characters, which is quite short and fits the pattern of an announcement rather than a full report. According to the rules, such announcements about board meetings and report approvals are best classified as Regulatory Filings (RNS) because they are general regulatory announcements and do not contain the actual report or financial data. Therefore, the appropriate classification is RNS with high confidence.
2019-03-06 English
VOLUNTARY ANNOUNCEMENT - SUBMISSION OF NDA TO U.S. FDA FOR LEVOAMLODIPINE MALEATE TABLETS
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the submission of a New Drug Application (NDA) to the U.S. FDA. It is an announcement of a specific event related to the company's drug development and regulatory progress. The document is short (2828 characters) and does not contain financial data, detailed financial reports, or management discussion. It is not an annual report, interim report, earnings release, or any detailed financial or governance report. It is also not a regulatory filing in the sense of officer certifications or compliance documents. The content is clearly an announcement of a significant corporate event (submission of NDA) rather than a report or detailed presentation. Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as a general category for regulatory announcements and miscellaneous filings that do not fit other specific categories.
2019-03-05 English
PROGRESS UPDATE ON THE PROPOSED SPIN-OFF AND SEPARATE LISTING OF CSPC XNW GROUP ON THE SHENZHEN STOCK EXCHANGE
Capital/Financing Update Classification · 95% confidence The document is an announcement from CSPC Pharmaceutical Group Limited regarding a progress update on the proposed spin-off and separate listing of CSPC XNW Group on the Shenzhen Stock Exchange. It discusses the proposed A share offering, lock-up undertakings by shareholders and senior management, and references previous announcements. The document contains no detailed financial statements or comprehensive financial analysis but rather provides information about the offering and related regulatory compliance. It is not a full financial report, earnings release, or management discussion. The document is longer than 5,000 characters and contains substantive information about the capital raising process and share lock-up arrangements, which are typical of capital/financing updates. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2019-03-04 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2019
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 28/2/2019, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, including share options, warrants, convertibles, and other share-related transactions. It includes confirmations by a company director regarding compliance with listing rules and legal requirements. The content focuses on share capital changes and securities issuance, typical of a monthly regulatory return on share capital movements rather than a full financial report or earnings release. It is not an announcement of a report publication but a substantive regulatory filing about share capital movements. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a regulatory return document that does not fit into more specific categories like Share Issue/Capital Change (SHA) because it is a formal monthly return to the exchange rather than a single event announcement.
2019-03-04 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.